Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 12  •  04:00PM ET
6.43
Dollar change
-0.32
Percentage change
-4.74
%
IndexRUT P/E10.19 EPS (ttm)0.63 Insider Own11.06% Shs Outstand51.25M Perf Week-6.68%
Market Cap329.72M Forward P/E229.64 EPS next Y0.03 Insider Trans-4.86% Shs Float45.61M Perf Month-1.98%
Enterprise Value127.94M PEG- EPS next Q-0.28 Inst Own69.24% Short Float19.80% Perf Quarter2.96%
Income57.24M P/S824.30 EPS this Y173.66% Inst Trans23.00% Short Ratio11.05 Perf Half Y21.78%
Sales0.40M P/B2.01 EPS next Y-97.55% ROA30.11% Short Interest9.03M Perf YTD15.44%
Book/sh3.19 P/C1.46 EPS next 5Y- ROE48.34% 52W High7.54 -14.72% Perf Year15.65%
Cash/sh4.40 P/FCF- EPS past 3/5Y58.40% 47.21% ROIC31.53% 52W Low3.93 63.50% Perf 3Y71.01%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-695.25% Volatility4.59% 4.27% Perf 5Y-87.01%
Dividend TTM- EV/Sales319.85 EPS Y/Y TTM147.55% Oper. Margin-18634.00% ATR (14)0.29 Perf 10Y-94.41%
Dividend Ex-Date- Quick Ratio6.65 Sales Y/Y TTM-100.00% Profit Margin14310.50% RSI (14)42.49 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio6.73 EPS Q/Q749.79% SMA20-6.64% Beta1.46 Target Price21.58
Payout- Debt/Eq0.15 Sales Q/Q- SMA50-2.11% Rel Volume1.44 Prev Close6.75
Employees136 LT Debt/Eq0.11 EarningsAug 14 BMO SMA2009.67% Avg Volume817.65K Price6.43
IPOSep 19, 1980 Option/ShortYes / Yes EPS/Sales Surpr.538.46% - Trades Volume1,181,250 Change-4.74%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Resumed Oppenheimer Outperform $19
Mar-05-25Initiated Oppenheimer Outperform $16
Jul-03-24Initiated H.C. Wainwright Buy $15
May-30-24Initiated Stifel Buy $21
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Sep-08-25 08:28AM
Sep-02-25 07:30AM
Aug-29-25 07:30AM
Aug-14-25 07:38AM
07:30AM
06:19AM Loading…
Aug-11-25 06:19AM
Aug-01-25 07:30AM
Jul-31-25 11:40PM
Jul-29-25 10:00AM
Jul-15-25 07:30AM
Jul-14-25 07:00AM
Jul-02-25 07:30AM
Jul-01-25 07:30AM
07:15AM
Jun-30-25 07:30AM
07:30AM Loading…
Jun-24-25 07:30AM
Jun-02-25 07:30AM
May-30-25 08:46AM
May-15-25 07:38AM
07:30AM
May-14-25 08:07AM
07:30AM
07:30AM
May-13-25 07:21AM
May-12-25 07:30AM
04:38AM
May-07-25 04:59PM
Apr-30-25 07:16AM
Apr-29-25 03:06PM
06:00AM
08:30AM Loading…
Apr-27-25 08:30AM
Apr-21-25 10:00AM
Apr-14-25 07:11AM
Apr-12-25 11:39AM
Apr-06-25 08:38AM
Apr-01-25 07:30AM
Mar-21-25 03:02AM
12:41AM
Mar-20-25 03:21PM
03:20PM
07:30AM
Mar-04-25 09:00AM
07:46AM
Mar-03-25 07:30AM
Feb-03-25 07:30AM
Dec-31-24 07:30AM
Dec-02-24 07:30AM
Nov-27-24 07:00AM
Nov-15-24 02:06AM
Nov-14-24 07:42AM
07:30AM
Nov-12-24 07:30AM
Nov-04-24 07:30AM
Nov-01-24 07:30AM
Oct-29-24 07:30AM
Oct-09-24 06:13PM
Oct-01-24 07:30AM
Sep-03-24 07:30AM
Sep-02-24 07:30AM
Aug-14-24 07:30AM
Aug-13-24 07:30AM
Aug-12-24 07:37AM
07:30AM
Aug-01-24 07:30AM
Jul-11-24 07:30AM
Jul-08-24 07:30AM
Jun-21-24 03:08AM
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
02:17AM
May-15-24 12:53PM
07:43AM
07:30AM
May-07-24 07:30AM
May-03-24 11:19AM
07:30AM
Apr-23-24 02:04PM
08:53AM
07:39AM
07:09AM
Apr-22-24 05:58PM
04:27PM
04:14PM
04:05PM
Apr-01-24 08:30AM
Mar-19-24 06:53AM
05:31AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
07:30AM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
Nov-13-23 12:23PM
07:41AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Crombez EricDirectorAug 14 '25Sale6.934,71832,68342,427Aug 15 04:30 PM
Vazzano Joseph WalterChief Financial OfficerAug 15 '25Sale7.3615,000110,358462,666Aug 15 04:30 PM
Vazzano Joseph WalterOfficerAug 15 '25Proposed Sale7.3615,000110,358Aug 15 04:15 PM
Vazzano Joseph WalterChief Financial OfficerJul 22 '25Sale6.641,5029,975477,666Jul 22 04:15 PM
Vazzano Joseph WalterOfficerJul 22 '25Proposed Sale6.641,5029,975Jul 22 04:11 PM
Silverstein Christine BerniDirectorJul 09 '25Sale5.8613,09376,669120,479Jul 10 04:30 PM
Seshadri VishwasChief Executive OfficerJul 09 '25Sale5.8669,420406,5031,234,341Jul 10 04:30 PM
Vazzano Joseph WalterChief Financial OfficerJul 09 '25Sale5.8625,411148,799479,168Jul 10 04:30 PM
Wuchterl Donald A.DirectorJul 08 '25Sale5.825,17630,147145,436Jul 10 04:30 PM
Charles Faith L.DirectorJul 09 '25Sale5.8610,73862,879139,094Jul 10 04:30 PM
O'Malley Brendan M.SVP, Chief Legal OfficerJul 09 '25Sale5.8617,428102,053360,817Jul 10 04:30 PM
Alvino MarkDirectorJul 09 '25Sale5.8613,09376,66977,252Jul 10 04:30 PM
Vazzano Joseph WalterOfficerJul 09 '25Proposed Sale5.8625,335148,354Jul 09 04:55 PM
Seshadri VishwasOfficerJul 09 '25Proposed Sale5.8669,215405,302Jul 09 04:52 PM
O'Malley Brendan M.OfficerJul 09 '25Proposed Sale5.8617,376101,749Jul 09 04:48 PM
Charles Faith L.DirectorJul 09 '25Proposed Sale5.8610,70662,691Jul 09 04:45 PM
Silverstein Christine BerniDirectorJul 09 '25Proposed Sale5.8613,05476,440Jul 09 04:40 PM
Alvino MarkDirectorJul 09 '25Proposed Sale5.8613,05476,440Jul 09 04:36 PM
Wuchterl Donald A.DirectorJul 08 '25Proposed Sale5.825,17630,147Jul 08 04:06 PM
Vazzano Joseph WalterChief Financial OfficerJun 06 '25Sale6.7617,795120,294491,246Jun 06 06:04 PM
Seshadri VishwasChief Executive OfficerJun 06 '25Sale6.7650,676342,5701,303,761Jun 06 06:00 PM
O'Malley Brendan M.SVP, General CounselJun 06 '25Sale6.7610,47070,777378,245Jun 06 05:56 PM
Vazzano Joseph WalterOfficerJun 06 '25Proposed Sale6.7617,795120,314Jun 06 04:13 PM
O'Malley Brendan M.DirectorJun 06 '25Proposed Sale6.7610,47070,789Jun 06 04:12 PM
Seshadri VishwasOfficerJun 06 '25Proposed Sale6.7650,676342,626Jun 06 04:11 PM
Alvino MarkDirectorMay 27 '25Sale6.382,00012,76090,435May 27 07:57 PM
Alvino MarkDirectorMay 27 '25Proposed Sale6.382,00012,762May 27 04:40 PM
Alvino MarkDirectorMay 16 '25Sale5.688,00045,44092,435May 16 05:23 PM
Alvino MarkDirectorMay 16 '25Proposed Sale5.688,00045,423May 16 04:07 PM
Seshadri VishwasChief Executive OfficerMar 31 '25Sale4.7825,000119,5001,355,322Mar 31 07:17 PM
Seshadri VishwasOfficerMar 31 '25Proposed Sale4.7825,000119,560Mar 31 04:08 PM
Alvino MarkDirectorJan 29 '25Sale5.384,00021,52064,334Jan 31 04:30 PM
Alvino MarkOfficerJan 29 '25Proposed Sale5.414,00021,640Jan 29 04:03 PM
Alvino MarkDirectorJan 21 '25Sale5.104,00020,40068,334Jan 21 04:30 PM
Alvino MarkOfficerJan 21 '25Proposed Sale5.224,00020,880Jan 21 04:05 PM